Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Universidad Nacional Autonoma de Mexico | OTHER |
Not provided
Not provided
Not provided
At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.
Analyze the difference in intravenous sedation requirements in patients with COVID-19. Patients who were assisted by a mechanical ventilator with sevoflurane versus conventional sedation.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anaconda Group | Use of Anaconda devide at any point during the initial follow up (7 days) additional of conventional intravenous sedation |
| |
| Non-Anaconda Group | Use on conventional intravenous sedation, not using Anaconda device |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sevoflurane with AnaConDa | Device | Sevoflurane administered with AnaConDa device |
|
| Measure | Description | Time Frame |
|---|---|---|
| Intravenous sedation requirements | Amount of intravenous sedation required | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Delirium | Number of patients that suffered delirium | Hospital stay (up to 30 days) |
| Acute kidney injury | Number of patients that suffered delirium |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with confired COVID-19 infection assited with mechanical ventilation that required sedation.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Manuel Lomeli, MD | Hospital H+ Queretaro | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital H+ Queretaro | Querétaro City | Querétaro | 76000 | Mexico |
Complete database will be shared as requested by the publishing journal, once the study is apporved.
Available one year after
Journal provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D012131 | Respiratory Insufficiency |
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Hospital stay (up to 30 days) |
| VAP | Number of patients that suffered ventilation acquired pneumonia | Hospital stay (up to 30 days) |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |